首页> 美国卫生研究院文献>BMC Gastroenterology >Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?
【2h】

Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?

机译:左氧氟沙星或克拉霉素为基础的四联疗法:在一个对两种抗生素都有高耐药率的国家作为根除幽门螺杆菌的一线治疗的最佳选择是什么?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background Helicobacter pylori eradication rates in Portugal are declining, due to increased resistance of this bacterium to antimicrobial agents, especially Clarithromycin. Quadruple Levofloxacin-containing regimens could be an option for first-line treatment, but its efficacy should be evaluated as fluoroquinolone resistance is rapidly increasing.Our aim was to compare the efficacy of Clarithromycin and Levofloxacin-based sequential quadruple therapies as first-line treatment options and determine factors associated with treatment failure.
机译:背景技术在葡萄牙,幽门螺杆菌的根除率正在下降,这是由于该细菌对抗菌剂(尤其是克拉霉素)的耐药性增加。含四联左氧氟沙星的方案可能是一线治疗的选择,但应评估其有效性,因为氟喹诺酮耐药性迅速增加。我们的目的是比较克拉霉素和基于左氧氟沙星的序贯四联疗法作为一线治疗方案的疗效并确定与治疗失败相关的因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号